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Introduction
The Joint United Nations Programme on HIV/AIDS 
(UNAIDS) estimates that the number of new HIV infections 
has declined by 35% since 2000 (UNAIDS, 2015a). The 
most significant reductions in new HIV infections have been 
among children below the age of 15 years, with transmission 
rates from mother-to-child decreasing by 58% since 2000 
(UNAIDS, 2014a). Many countries, even those with high HIV 
burdens, have made significant progress towards eliminating 
mother-to-child transmission of HIV (UNAIDS, 2015b). Yet 
despite these encouraging trends, the number of new HIV 
infections each year remains unacceptably high. In 2014 
an estimated 2 million new HIV infections were recorded, 
translating to about 5 600 people acquiring HIV daily. 
HIV continues to spread in key populations, such as sex 
workers, men who have sex with men (MSM), transgender 
individuals and people who inject drugs, where the risk 
of HIV is highest. However, sub-Saharan Africa remains 
the most heavily burdened area with 66% of all new 
HIV infections occurring in this region. In this region, 
adolescent girls and young women aged 16–24 years bear a 
disproportionate burden of HIV infection. About 380 000 new 
HIV infections occur in this age group each year (UNAIDS, 
2014a) and these young women experience HIV rates up to 
eightfold higher (UNAIDS, 2010) and acquire HIV infection 
at least five years earlier than their male peers (Abdool 
Karim, Abdool Karim, Singh, Short, & Ngxongo, 1992; 
Shisana, et al., 2009). One of the most crucial challenges in 
HIV prevention in Africa is reducing the high infection rates 
among young women.
In this paper we examine the available behavioural, 
structural and biomedical HIV prevention options, as well 
as new prevention technologies under development, with a 
particular focus on strategies that are appropriate for young 
women. The potential HIV prevention options that could be 
combined and tailored for young women are discussed. 
This paper does not attempt to provide a comprehensive 
overview of all HIV prevention options available. For 
example, prevention of vertical transmission and prevention 
of parenteral transmission are not specifically discussed in 
this paper.
Structural and behavioural interventions 
Abstinence, monogamy and condom use
Since the beginning of the epidemic, HIV prevention 
programmes have promoted the “ABC” strategies that 
encourage sexual abstinence, a reduction in the number of 
multiple and concurrent sexual partnerships (be faithful) and 
the use of condoms. Individuals who are sexually abstinent 
or practice lifelong mutual monogamy have a minimal risk 
of HIV infection. Unfortunately, women have limited control 
over whether their male partners remain faithful. Further, 
as a prevention strategy on its own, the promotion of 
abstinence has had little to no impact on HIV prevention. 
One systematic review involving 15 940 youths showed 
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that sexual abstinence only programmes had no impact on 
incidence of unprotected vaginal sex, number of partners, 
condom use or sexual initiation (Underhill, Montgomery, & 
Operario, 2007). 
Male and female condoms are an essential component 
of HIV prevention programmes. They are inexpensive and, 
when used correctly and consistently, provide protection 
against acquisition and transmission of HIV, a variety of 
other sexually transmitted infections (STIs) and pregnancy 
(Holmes, Levine, & Weaver, 2004). In HIV sero-discordant 
studies, condom use has been shown to effectively prevent 
HIV transmission. Condom promotion programmes, 
particularly for sex workers, have also had a substantial 
impact on HIV epidemics in some countries, particularly in 
the early stages of the epidemic (Rojanapithayakorn, 2006). 
However, for condoms to be effective as a prevention 
option at a population level they need to be widely 
accessible. Although high condom coverage has been 
achieved in some countries, in sub-Saharan Africa, only 
eight condoms on average are estimated to be available per 
year for each sexually active individual (UNAIDS, 2014a). In 
South Africa the distribution of male condoms has increased 
drastically from 376 million units in 2006 to 723 million units 
in 2014. Although not on the same scale, female condom 
distribution has increased from 3.6 million units in 2006 to 20 
million units in 2014 (National Department of Health, 2015). 
Despite the proven effectiveness and increasing 
availability, inconsistent use of condoms limits their potential 
population-level effect. A wide range of factors hinder 
condom use, the most common being the perception that 
condoms make sex less pleasurable (Mnyika, Kvale, & 
Klepp, 1995) and requesting that a partner uses a condom 
implies self-acknowledgement of HIV infection or a lack 
of trust in the partner (Bedimo, Bennett, Kissinger, & 
Clark, 1998). Condom use is often low among married 
couples and in stable partnerships where pregnancy is 
desired (Hendriksen, Pettifor, Lee, Coates, & Rees, 2007; 
Maharaj & Cleland, 2004). Further, because of gender 
power imbalances, many women find it particularly difficult 
to negotiate condom use with their partners. A partner’s 
agreement and cooperation is also required to use female 
condoms. Condoms are therefore a prevention option that is 
often under the control of a woman’s partner.
Other factors associated with inconsistent condom use 
are alcohol consumption and substance abuse. This trend 
is particularly problematic because many individuals meet 
high-risk sexual partners in social settings where alcohol or 
drugs are available. 
Despite these challenges, condoms are highly effective 
when used consistently and some people do successfully 
use condoms to prevent both STIs and pregnancy and 
they should therefore be offered as part of HIV prevention 
packages for all populations and in all settings.
Behaviour change interventions
Numerous social and behavioural change interventions to 
prevent HIV have been assessed. Examples include peer 
education (Medley, Kennedy, O’Reilly, & Sweat, 2009), mass 
media communication (Bertrand, O’Reilly, Denison, Anhang, 
& Sweat, 2006), school-based sex education programmes 
(Fonner, Armstrong, Kennedy, O’Reilly, & Sweat, 2014), 
microfinance or skills development projects (Kennedy, 
Fonner, O’Reilly, & Sweat, 2014), and behavioural 
counselling (Zajac et al., 2015). Most of the studies find 
a moderate improvement in behavioural outcomes, for 
example, increased HIV knowledge, increased condom use, 
and reduction in high-risk sexual behaviour, but few show a 
significant impact on biological outcomes such as reduction 
in HIV incidence. One systematic review in 2010 of 11 
behaviour change studies, assessing 8 unique interventions, 
showed that only 1 study resulted in a reduction of HIV 
incidence. This study, which was conducted among 541 
female sex workers in India and included group educational 
and motivational sessions over 6 months and was shown 
to reduce HIV incidence after 1 year of follow-up (incidence 
rate ration [IRR] = 0.33, 95% CI: 0.15 to 0.72) (Bhave et 
al., 1995). More recently the Safe Homes And Respect For 
Everyone (SHARE) trial, a community-level mobilisation 
intervention in Uganda to change attitudes, social norms and 
behaviours related to intimate partner violence was shown 
to be associated with a 33% reduction in HIV incidence 
(adjusted incidence rate ratio [aIRR] = 0.67, 95% CI: 0.46 to 
0.97, p = 0.036) (Wagman et al., 2015). Addressing gender-
based violence and encouraging greater male responsibility 
are critical short- to medium-term interventions. Gender-
based violence is often a consequence of the power 
imbalance between men and women in relationships and 
compounds a young woman’s vulnerability to HIV infection 
(Abdool Karim, Sibeko, & Baxter, 2010a).
HIV counselling and testing (HCT)
Knowledge of HIV status is a fundamental component 
of any treatment or prevention programme and should 
therefore be offered as part of HIV prevention packages 
for all populations and in all settings. HIV counselling and 
testing (HCT) is effective in reducing risky sexual behaviours 
and has been shown to be a cost-effective prevention 
intervention (Sweat et al., 2000; The VCT Efficacy Study 
Group, 2000). However, many people remain unaware of 
their HIV status and estimates from UNAIDS indicate that 
about 52% of all people living with HIV do not know their 
status (UNAIDS, 2014a). Denial, stigma, and a lack of 
understanding of vulnerability and risk contribute to low 
HIV testing rates. Discrimination and social marginalisation 
continue to be experienced daily by people who are the most 
affected by HIV, further contributing to their reluctance to 
test for HIV (Abdool Karim, 2011).
Ambitious global targets for HIV testing and treatment 
have been set and aim to have 90% of people living with 
HIV knowing their HIV status, 90% of people who know 
their status receiving treatment and 90% of people on HIV 
treatment having a suppressed viral load by 2020 (UNAIDS, 
2014b). Reaching these targets by 2020 will require rapid 
scale up of HIV testing and innovative ways to reach 
populations who do not yet know their HIV status. Strategies 
such as provider-initiated testing (Kennedy et al., 2013), 
community-based voluntary counselling and testing (Coates 
et al., 2014) and home-based testing (Sekandi et al., 2011) 
are some of the initiatives that have been implemented to 
improve HCT uptake.
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Cash incentives for HIV prevention
The use of cash transfers (conditionally or unconditionally) 
to achieve desired behaviours or health outcomes has 
been shown to be successful in several different settings. 
For example, cash incentives programmes have been 
effective in smoking cessation programmes (Volpp et al., 
2009), substitution therapy for drug abuse (Petry et al., 
1998; Sindelar, Olmstead, & Peirce, 2007), and improving 
immunisation coverage and family planning utilisation 
(Barber & Gertler, 2008; Fernald, Hou, & Gertler, 2008). 
Cash transfers are also being evaluated for their potential 
to reduce HIV risk, especially among young women. A 
systematic review of cash transfer studies in 2012 identified 
16 studies, 10 of which had been completed. Most of the 
studies have been conducted in adolescents and most 
report reductions in risky sexual behaviour such as delaying 
sexual debut, staying in school and condom use (Pettifor, 
MacPhail, Nguyen, & Rosenberg, 2012). One cluster trial in 
Malawi of cash incentives for school attendance showed that 
weighted prevalence of HIV at 18 months was lower in the 
intervention communities (Baird, Chirwa, McIntosh, & Ozler, 
2010). A case control study, that assessed the publically 
funded social grant programme on risk of HIV infection in 
adolescents from South Africa, showed that cash transfers 
were associated with a 51% decrease in transactional sex 
and a 71% reduction in age-disparate sex in girls but had no 
impact on boys (Cluver et al., 2013).
Two trials that directly assessed HIV incidence as the 
main outcome found no impact of cash transfers on HIV 
incidence. The HPTN 068 Swa Koteka study (n = 2 448), 
which provided a cash incentives for school attendance, 
showed that there was no difference in HIV acquisition 
between the young women who received the cash transfer 
and those that did not (Pettifor et al., 2015). The CAPRISA 
007 cluster randomised controlled trial (CAPRISA 007), 
which was undertaken with 3 217 consenting male 
(n = 1 517) and female (n = 1 700) students in grades 9 
and 10 in 14 schools in rural KwaZulu-Natal, South Africa, 
showed that conditional cash incentives for meeting any 
combination of four conditionalities (annual HIV testing, 
school performance, participation in a HIV prevention 
programme and participation in a community project) was 
associated with a 30% reduction in herpes simplex virus type 
2 (HSV-2) incidence, but did not have sufficient statistical 
power to demonstrate an impact on HIV incidence (Abdool 
Karim et al., 2015) (Table 1).
The implementation of behavioural interventions or cash 
transfer programmes for HIV prevention in young women 
would need to be evaluated in the specific context and 




Since 2010 the evidence for the protective benefits of oral 
pre-exposure prophylaxis (PrEP) has been consistently 
growing and includes a range of settings and populations. 
Results from several randomised double-blinded placebo-
controlled trials of tenofovir-containing PrEP for the 
prevention of sexual transmission of HIV, provide consistent 
evidence of efficacy in men (Baeten et al., 2012; Grant et al., 
2010; McCormack et al., 2016; Molina et al., 2015; Thigpen 
et al., 2012), but not in women (Marrazzo et al., 2015; Van 
Damme, et al. 2012). Daily oral PrEP has also been shown 
in one study to be effective in a population of people who 
inject drugs (Choopanya et al., 2013).
In women, although two trials (Partners PrEP and 
Botswana TDF2) demonstrated effectiveness of oral PrEP 
ranging from 66% to 75%, two other trials (the FEMPrEP 
(Van Damme et al., 2012) and VOICE (Marrazzo et al., 2015) 
trials) showed no protective effect of PrEP in this group 
(Table 1). Analysis of drug concentrations revealed that 
<30% of the women in these trials were able to adhere to the 
prescribed intervention (Marrazzo et al., 2015; Van Damme 
et al., 2012). Therefore, just like condoms, consistent use is 
essential for the intervention to be effective. 
In 2015 the World Health Organization (WHO) released 
guidelines for oral PrEP (World Health Organization, 2015). 
The guidelines recommend that “oral PrEP (containing 
Tenofovir Disoproxil Fumarate [TDF]) should be offered as 
an additional prevention choice for people at substantial 
risk of HIV infection (defined as HIV incidence >3%) as 
part of combination prevention approaches” (World Health 
Organization, 2015, p. 14). These guidelines combined with 
the approval of tenofovir-containing PrEP for HIV prevention 
by several countries including the USA, France, South Africa 
and Kenya, has made the use of PrEP for HIV prevention a 
possibility. PrEP is a particularly important HIV prevention 
option for women, as it is one of the few strategies that can 
be directly controlled by a woman. 
The challenge now is to determine how best to implement 
PrEP in the populations that would benefit most, while still 
maintaining high levels of adherence. 
Long-term, high adherence is essential for PrEP to be 
successful. Poor adherence may lead not only to sub-optimal 
protection, but may also have an impact on drug resistance. 
While clinical trials may achieve high adherence, the same 
may not pertain to “real world” settings where PrEP may be 
implemented in under-developed public healthcare facilities 
without adequate attention to adherence support. Evidence 
from a clinical practice setting in the US, however, shows 
that PrEP scale-up with high adherence is possible and none 
of the 653 MSM followed for a mean of 7.2 months after 
initiating PrEP have acquired HIV (Volk et al., 2015). Clinical 
trials of PrEP among young women in Africa, a group that is 
at particularly high risk of HIV have encountered significantly 
more challenges with adherence than trials in MSM. Data 
on effective PrEP adherence strategies in young women are 
limited, making it difficult for programmatic scale-up to use 
proven evidence-based approaches for adherence in this 
group.
The concerns about adherence to PrEP should certainly 
not hinder its implementation; similar concerns were raised 
when antiretroviral therapy (ART) first became available as 
treatment and was actually used as an argument against 
the implementation of these life-saving drugs in Africa. The 
scale up of ART roll-out programmes to over 15 million 
people has demonstrated that high levels of adherence are 
possible, even in resource-constrained settings. Further, the 
product’s effectiveness may serve as strong motivation for 
adherence (Amico & Stirratt, 2014). Regardless, adherence 
is likely to be a challenge that will require a concerted effort 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































to overcome and PrEP programmes will need to include 
practical and proven adherence support programmes.
There are several other factors that may hinder PrEP 
implementation. Firstly, given that PrEP is a new HIV 
prevention strategy for many countries, the implementation 
of PrEP will need to be accompanied by advocacy and 
community outreach to increase awareness and knowledge. 
Several studies in the US have shown that PrEP awareness 
among physicians is suboptimal (Mimiaga, White, Krakower, 
Biello, & Mayer, 2014) and there is limited immediate uptake 
by individuals who could benefit from PrEP (Liu et al., 2008; 
Rucinski et al., 2013). Secondly, before PrEP can be initiated, 
the HIV status of the individual must be established and 
ongoing access to HIV testing will be an important component 
of any PrEP roll-out programme. Thirdly, when resources 
are scarce, it is necessary to rationalise and prioritise certain 
high risk groups for access to interventions over others. 
Determining who would benefit most will vary from country 
to country and while some groups, like MSMs, are easily 
identifiable, determining who should have access or be 
prioritised in generalised epidemics is more complex. In South 
Africa, for example, although young women are considered 
to be a group at high risk of HIV infection, sex workers have 
been prioritised for the implementation of PrEP (Department 
of Health, 2016) and it may take several years before PrEP is 
available to young women through the public sector.
However, the ongoing demonstration projects in a range of 
populations will help inform scale up of PrEP in populations 
like young women. Initiatives like the PEPFAR-funded 
DREAMS initiative, which aims to help adolescent girls 
develop into determined, resilient, empowered, AIDS-free, 
mentored and safe women, will provide the necessary 
resources for scaling up PrEP in this vulnerable group. 
Microbicides for the prevention of HIV
Microbicides, which are topical agents applied in the 
genital tract or rectum to prevent HIV infection, have been 
in development since the early 1990s. A safe and effective 
microbicide is a particularly important HIV prevention 
strategy for women because it offers them the opportunity 
to control their own HIV risk. Over the past 23 years, 12 
advanced clinical trials of 7 candidate products (some tested 
as multiple doses and formulations) have been completed. 
The CAPRISA 004 tenofovir gel trial (Abdool Karim et al., 
2010b), was the first to demonstrate a significant reduction 
in HIV acquisition in women. This trial showed that tenofovir 
gel, when used before and after sex, reduced HIV acquisition 
by 39% and HSV-2 by 51% (Abdool Karim et al., 2010b). 
Despite these encouraging results, two other trials, which 
also assessed tenofovir gel, failed to show a protective 
effect. The Follow-on African Consortium for Tenofovir 
Studies (FACTS) trial (Rees, et al., 2015) of peri-coital gel 
reported 0% (95% CI: −40;30) protection and the Vaginal 
and Oral Interventions to Control the Epidemic (VOICE) trial 
(Marrazzo et al., 2015) of daily gel reported an estimate of 
15% (95% CI: −21;39). Suboptimal adherence was the main 
reason for the variability in HIV outcomes across these trials. 
An analysis of drug levels revealed that only 25% of women 
assigned to tenofovir gel in the VOICE trial (Marrazzo et al., 
2015) and about half of the women in the FACTS trial (Rees 
et al., 2015) had detectable drug levels. 
Although research on tenofovir gel is continuing, 
including its potential as a rectal microbicide in MSM in 
several countries, the microbicide field has shifted its focus 
towards developing products that are less dependent 
on user compliance and products that can meet multiple 
sexual reproductive health needs. Data from two efficacy 
trials evaluating the long-acting antiretroviral dapivirine 
intravaginal ring were recently released. These studies 
showed that the dapivirine vaginal ring reduced HIV 
incidence by 27% (95% CI: 1% to 46%) in the ASPIRE (A 
Study to Prevent Infection with a Ring for Extended Use) trial 
and by 31% (95% CI: 1 to 51%) in the Ring trial (Baeten 
et al., 2016; International Partnership for Microbicides, 
2016). While the effectiveness of the dapivirine vaginal ring 
in preventing HIV is considerably lower than anticipated 
and hoped for, the success of the two trials in achieving 
high levels of adherence (82% in ASPIRE and 73% in the 
Ring Study) and regular monthly vaginal ring insertions, is 
encouraging. However, the results show that protection 
differed by age; with no protection observed in young 
women below the age of 21 years. An analysis of drug levels 
in plasma samples shows that adherence in the younger 
women was two- to fourfold lower than in women older than 
21 years (Baeten et al., 2016). More research is needed to 
fully understand and overcome the remaining challenges 
for sustained adherence in this high-risk population. An 
open label post-trial access study is now planned, which will 
include focus group discussions with the women, and will 
hopefully contribute to our understanding of the contextual 
factors that have an impact on adherence in young women.
In addition to new formulations and delivery devices, future 
microbicide development is likely to focus on a combination 
of antiretroviral drugs and products that meet multiple sexual 
and reproductive health needs, for example, combinations of 
antiretroviral agents with contraceptives.
Prevention benefits of antiretroviral treatment
Remarkable progress has been made in scaling up ART as 
a treatment for AIDS. By mid-2015, a total of 15.8 million 
people living with HIV were receiving ART. In addition to 
averting an estimated 7.8 million deaths globally between 
2000 and 2014 (UNAIDS, 2015a), there is compelling 
evidence that treatment of HIV infected individuals can 
prevent sexual transmission of HIV. Several studies have 
demonstrated that heterosexual HIV transmission is closely 
correlated with viral load (Fideli et al., 2001) and that the 
risk of transmission is very low when the HIV-infected 
individuals receiving ART have a suppressed viral load. A 
systematic review and meta-analysis of studies that included 
5 021 heterosexual couples and 461 HIV-transmission 
events showed that there were no transmission events 
from seropositive partners who had a viral load <400 
copies/ml on ART (Attia, Egger, Müller, Zwahlen, & Low, 
2009). Observational data from the PARTNERS study, 
which included HIV serodiscordant heterosexual and 
MSM couples, show that when the HIV-positive partner’s 
viral load was below 200 copies/ml there were zero linked 
transmission events (Rodger et al., 2014). 
The HPTN 052 trial provides the most compelling 
evidence of the prevention benefits of ART (Table 1). In this 
trial interim results showed that early ART initiation (CD4 cell 
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count >350 cells/mm3) in the HIV-positive partner led to a 
96% reduction in HIV transmission among HIV discordant 
couples from 9 countries (Cohen et al., 2011). Following 
the release of these results, all participants in the deferred 
arm were offered immediate ART and the trial cohort was 
followed up for a further four years. Final results show that 
there was an overall 93% reduction in transmission among 
those on ART (Cohen & the HPTN 052 study team, 2015). 
The findings demonstrate the sustained protection against 
transmission provided by ART and the vital importance of 
ensuring treatment adherence and viral suppression.
If implemented on a large enough scale, the treatment 
as prevention strategy has the potential to alter the HIV 
epidemic. Evidence from one rural community in KwaZulu-
Natal shows that a modest 30–40% ART coverage 
resulted in a 38% reduction in new HIV infections between 
2004 and 2011 (Tanser, Barnighausen, Grapsa, Zaidi, & 
Newell, 2013). However, women have little control over 
whether their HIV-positive male partners will have an HIV 
test, agree to take ART and to take their ART with high 
adherence. 
Medical male circumcision
Voluntary medical male circumcision (VMMC) is an important 
biomedical HIV prevention option for heterosexual men 
and has been shown to reduce the risk of female-to-male 
transmission of HIV by up to 66% (Siegfried, Muller, Deeks, 
& Volmink, 2009), with three independent randomised 
controlled trials in South Africa (Auvert et al., 2005), Kenya 
(Bailey et al., 2007) and Uganda (Gray et al., 2007) showing 
consistent findings. Although VMMC may provide some 
indirect benefits to women over time by reducing exposure 
to HIV, there is limited epidemiological evidence showing a 
direct protective effect of male circumcision on reducing HIV 
in women (Weiss, Hankins, & Dickson, 2009). 
VMMC has become a priority component of HIV 
prevention programmes and is being scaled up in 14 
priority countries that have a high HIV burden. About 10 
million men in Eastern and Southern Africa are estimated 
to have undergone VMMC for HIV prevention since its 
implementation in 2009.
In South Africa VMMCs have increased from just 5 190 
in 2008 to approximately 2.1 million by January 2015 
(Careworks, 2016). In the Orange Farm district, the scale up 
of VMMC from 12% in 2007 to 53% in 2010 has led to a 
19% reduction in HIV prevalence and up to 61% reduction 
in incident HIV infection (Auvert et al., 2013), providing 
evidence of a population level impact of circumcision. 
Despite these remarkable achievements, more needs to 
be done to reach the ambitious global target of 20 million 
circumcisions (80% coverage) by 2020 (UNAIDS, 2014a, 
b). Targeting of VMMC to young men, demand creation 
for and uptake of VMMC by early adopters are some of 
the innovative approaches being utilised in sub-Saharan 
Africa to increase uptake of VMMC (Montague et al., 2014). 
Other innovative strategies being implemented to help 
countries accelerate access to VMMC services include 
simplified procedures and new circumcision devices, which 
may facilitate task-shifting of circumcisions from doctors to 
mid-level health professionals, including nurses (Mutabazi et 
al., 2014; Sokal et al., 2014). 
Treatment of sexually transmitted infections
STIs are a major contributor to the global burden of disease, 
causing substantial illness, severe medical complications 
and infertility. The presence of STIs, particularly those 
that cause genital ulceration or inflammation has been 
shown to play an important role in the transmission of HIV 
by increasing the infectiousness of people living with HIV 
and the susceptibility of HIV-negative individuals (Chen 
et al., 2007; Cohen, 1998; Wald & Link, 2002). HSV-2, for 
example, has been shown to be associated with a 2.8 and 
3.4-fold increased risk of HIV acquisition in men and women 
respectively (Glynn, Biraro, & Weiss, 2009). Accumulating 
data indicates that human papillomavirus (HPV), one of the 
most common STIs worldwide, may also be an important 
cofactor in HIV acquisition in men and women. A systematic 
review and meta-analysis in 2012 showed that the overall 
risk of HIV acquisition in women doubled when they had 
a prevalent HPV infection (hazard ratio [HR] = 2.06 (95% 
CI: 1.44–2.94) (Houlihan et al., 2012). The presence of 
bacterial vaginosis has also been linked to an increased risk 
of HIV infection. A meta-analysis of studies that included 
30,739 women shows that bacterial vaginosis infection was 
associated with a 1.6-fold increased risk of HIV infection 
(Atashili, Poole, Ndumbe, Adimora, & Smith, 2008). The 
burden of these STIs is particularly severe in sub-Saharan 
Africa and especially in young women.
An improved STI case management intervention, which 
was implemented in the early stages of the HIV epidemic, 
was shown in one community randomised controlled trial 
(The Mwanza trial) in rural Tanzania to reduce incident HIV 
infections among 12 537 individuals by 42% (Grosskurth 
et al., 1995). Eight subsequent STI treatment trials were 
unable to replicate this finding, possibly due to the maturing 
HIV epidemic and lower-risk behaviours in the populations 
participating in the trials (Korenromp et al., 2005). 
Nevertheless, treatment of STIs remains an important public 
health priority whether it affects HIV transmission or not, 
in epidemiological settings that have subpopulations with 
a substantial burden of curable STIs. Since STIs and HIV 
have a common route of transmission, STI treatment should 
be included as part of HIV prevention programmes for both 
men and women in these settings. 
HIV prevention combinations for young women
Several evidence-based behavioural, structural and 
biomedical HIV prevention interventions are available and 
are described above. Currently, limited data are available 
on how these separate interventions will work when 
implemented together. It is therefore challenging to define 
what an effective combination HIV prevention package 
should look like across contexts. 
Given that HIV epidemics in communities are complex 
and comprise a mosaic of different risk factors and different 
routes of transmission, a single “one size fits all” approach 
to HIV prevention is unlikely to be able to alter the epidemic 
trajectory. Rather, a mixture of prevention strategies 
that combines biomedical, behavioural, and structural 
interventions and are tailored for specific key locations and 
priority populations is needed. The optimal combination will 
vary by population and location and different combinations 
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may be needed even in the same country. Several trials 
are currently underway to study various combinations of 
strategies in different populations and settings will expand 
the evidence base for impact (Table 2). 
Based on available evidence, an HIV prevention package 
for a young woman in Africa, could include HCT with 
linkage to ART (if positive), prevention of mother-to-child 
programmes (if pregnant) or PrEP (if negative), condom 
promotion, treatment of STIs (in regions with a high burden 
of STIs), behaviour change communication that reinforces 
key sexual risks such as having multiple partners and 
age-disparate sex, social protection interventions including 
cash transfer or other economic empowerment strategies in 
some settings, gender-based violence education and VMMC 
(for her male partner) (Figure 1). As with contraceptive 
choices, the package of HIV prevention options ultimately 
adopted by a woman will depend on her personal situation 
and may even change throughout her life course or her 
relationship status. 
Despite the growing number of HIV prevention options 
available, the number of strategies that empower women 
to directly control their risk of HIV remain limited. Therefore, 
ongoing research for new HIV prevention technologies, 
particularly ones that can be controlled by women, remains 
an essential tool in the fight against the HIV epidemic in 
sub-Saharan Africa. 
HIV prevention strategies under development
Long-acting biologicals 
Other promising HIV prevention strategies being explored 
are long-acting biologicals. Long-acting antiretroviral 
injectable agents such as rilpivirine (TMC278) and 
cabotegravir (GSK1265744), which can be administered 
every 2 to 3 months, are in early stages of clinical testing 
as potential microbicide/PrEP agents. Several potent 
and broadly neutralising antibodies (bNAbs) such as 
VRC01, PGT121 and CAP256-VRC26.25, which have 
been shown to prevent infection and reduce viral load in 
non-human primates, are also being developed as a passive 
immunisation prevention strategy in humans. 
If these new products are shown to be effective, they 
have the potential to overcome the adherence challenges of 
topical and oral PrEP and could substantially expand HIV 
prevention options, particularly for young women.
Vaccines
A safe and efficacious vaccine to prevent HIV infection 
remains an important global goal but its development has 
proved challenging. Glimmers of hope that an HIV vaccine 
is possible emerged with the findings from the RV144 trial 
in Thailand (Rerks-Ngarm et al., 2009) (Table 1), which 
showed a protective effect of 31.2% (95% CI, 1.1 to 52.1; 







































Figure 1: HIV prevention for young women — examples of prevention options that could be used in combination (as appropriate) to prevent 
HIV infections in young women





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































made in the vaccine field. Specifically, scientific advances 
in understanding the types of immune responses that may 
contribute to a vaccine’s protective effect (Corey et al., 2015; 
Liao et al., 2013; Moore et al., 2012), discovery of new 
sites for neutralisation, including a site at the gp120-gp41 
interface, isolation of several new potent neutralising 
monoclonal antibodies (Doria-Rose et al., 2014), and highly 
effective new strategies to deliver HIV vaccines (Hansen 
et al., 2013) have been identified. Pre-clinical studies have 
also shown that bNAbs may also have therapeutic benefits 
(Barouch et al., 2013). 
In 2015 the Pox-Protein Public Private Partnership (P5) 
launched a trial in South Africa that will assess a modified 
version the RV144 vaccine strategy. Several early phase 
I and II vaccine trials are underway testing a variety of 
candidates and vaccine concepts (AVAC, 2015). Research 
on bNAbs is also accelerating, with potential promise for 
future prevention, treatment and cure strategies.
Scaling up prevention interventions
To realise the goal of ending the AIDS epidemic as a public 
health threat by 2030, the number of new HIV infections 
globally will need to be drastically reduced to fewer than 
500 000 by 2020 (UNAIDS, 2014b). To achieve this 
ambitious target, proven HIV prevention strategies will need 
to be rapidly scaled up and focused on the populations and 
locations in greatest need. 
Mathematical modelling of data from Kenya shows how 
the impact of combination HIV prevention can be enhanced 
through prioritisation of the population and locations 
in greatest need. The universal implementation of a 
combination HIV prevention package in Kenya that includes 
VMMC, behaviour change communication, early ART and 
PrEP could reduce the total number of new HIV infections 
by 40% during a 15-year period. However, when the HIV 
prevention package was tailored to reflect patterns in local 
epidemiology, the overall impact was increased by 14% 
during the 15 years (Anderson et al., 2014).
The estimated resources required to achieve the ambitious 
goal of ending the AIDS epidemic as a public health threat 
by 2030 are substantial. UNAIDS estimates that domestic 
and international investment in HIV programmes will need to 
increase from an estimated US$19.2 billion available in 2014 
to US$26.2 billion by 2020 (UNAIDS, 2016). Whether low- and 
middle-income countries will be able to meet the estimated 
450% and 530% increase in funding needed is questionable.
Conclusion
Despite substantial progress in reducing HIV infections, 
the epidemic continues to spread in some locations and 
mainly in key and vulnerable populations. A range of 
behavioural, structural and biomedical HIV prevention 
options are available. Scaling up these proven HIV 
prevention strategies in combination will be the most 
effective way to reduce the number of new HIV infections 
to fewer than 500 000 by 2020 (Piot et al., 2015). The 
combination of HIV prevention interventions needed 
will vary depending on cultural context, the population 
targeted, the location and the stage of the epidemic. 
Appropriate HIV prevention strategies for young women 
in Africa include HCT, with linkage to ART (if positive) 
or PrEP (if negative), condom promotion, treatment of 
STIs, behaviour change communication, social protection 
interventions including cash transfer or other economic 
empowerment strategies in some settings as well as 
ART for HIV-positive male partners, gender-based 
violence education and VMMC (for her male partner). 
The development of new long-acting biologicals for HIV 
prevention as well as a safe and effective HIV vaccine will 
substantially advance the progress towards eliminating 
HIV as a public health threat. 
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